Table 1. Selected combinations of CA19-9 with other biomarkers.

Combination of biomarkers	Sensitivity	Specificity	Pub. date	Cohorts
CA19-9+CA125+LAMC2	84.7	89.2	2014	PDAC vs. benign controls
CA 19-9+CA 242	89	75	2015	PC vs. benign and healthy controls
CA 19-9+CA 125+CEA+CA242	90	94	2015	PC vs. healthy controls
CA19-9+5MC+H2A1.1+H2AZ+H3K4Me2	92	90	2015	PC vs. benign and healthy controls
CA 19-9+albumin+IGF-1	94	95	2016	PDAC vs. CHP and healthy controls
CA 19-9+MUC5A	75	83	2017	PC vs. CHP and benign controls
CA 19-9+CEA+HGF+OPN+ctDNA	64	99.5	2017	PDAC vs. healthy controls
CA 19-9+THBS2	87	98	2017	PDAC vs. benign and healthy controls
CA 19-9+MDMs	92	92	2021	PDAC vs. healthy controls

Note: PDAC, pancreatic ductal adenocarcinoma; PC, pancreatic cancer; CHP, chronic pancreatitis; benign, benign pancreatic disease.